Developing a Novel Approach for the Future of Breast Cancer Diagnosis and Treatment
PARK CITY, UT / ACCESSWIRE / October 5, 2022 / NuView Life Sciences, Inc ("NuView", the "company"), is a clinical stage precision oncology company focusing on innovative approaches, such as theranostics, to diagnose and treat cancer. The field of theranostics, combines molecular imaging (PET, PET/CT, PET/MRI) with targeted radionuclide therapy, which involves the use of small molecules, peptides, and/or antibodies for targeted delivery of therapeutic radionuclides. The exponential, global expansion of theranostics in oncology stems from its potential to target and eliminate tumor cells with minimal adverse effects, resulting in a mechanism of action that differs distinctly from that of most other systemic therapies.
NuView is leveraging its clinical stage small molecule, NV-VPAC1, to advance its unique theranostic technology for precision diagnostics and targeted therapy. NV-VPAC1 binds directly to VPAC1 receptors found in high densities in breast cancer tumors. Since VPAC1 is overexpressed on estrogen-dependent and independent mechanisms of human breast cancer cells, NV-VPAC1 can target many different forms of breast cancer.
The emerging field of theranostics is becoming more prominent in the healthcare industry and is considered a more streamlined and sophisticated method of treatment. With FDA approval being sought for NV-VPAC1, there is the potential to attain tremendous benefit. Prospective advantages include: the ability to differentiate malignant from benign breast lesions regardless of the level of density (BI-RADS) and the ability to improve the quality of life in patients while they are being diagnosed. Physicians and caregivers understand the stress and anxiety a patient and their families endure during the initial phase of diagnosis. Until now there has been no diagnostic test available that would quickly and efficiently lessen that anxiety. This technology reduces the chance of false positive results which decreases the need for invasive biopsies.
NuView is taking a modern approach to cancer identification and treatment based on molecular expressions to complement the current mammogram standard of care," stated Jill Helmke, D.Ph., N.Ph., Chief Pharmacy Officer and Director of Clinical Trials. "Identifying cancer through molecular imaging allows doctors to make a more informed decision about whether to biopsy a lesion. "
Paul Crowe, Chairman and Chief Executive Officer, remarked "NuView's mission is to improve the way cancer is diagnosed and treated to ease the burden of stress and anxiety on patients and families while they await the initial diagnosis or treatments. Dr. Mathew Thakur, Thomas Jefferson University, who invented the technology believes, "NuView's NV-VPAC1 should offer healthcare providers a new strategy that provides clear test results, ease of use, and efficient use of time that benefits patients, doctors, and the healthcare system at large."
NuView's NV-VPAC1 is a versatile platform technology that, in addition to targeting breast cancer, has also been utilized for a variety of preclinical and clinical studies for other cancer indications including brain, bladder, lung, prostate, cervical, and colon. Further updates related to these additional clinical indications will be forthcoming.
About NV-VPAC1™
NuView's technology, branded NV-VPAC1™, consists of a small molecule peptide construct that targets the vasoactive intestinal peptide receptor type 1 (VPAC1), a part of the G protein-coupled receptor family. The VPAC1 receptor becomes highly overexpressed on the cell surface of a variety of cancers including brain, breast, lung, bladder, prostate, cervical, and colon. Attaching a molecular imaging or therapeutic passenger to NV-VPAC1 enables NuView to develop a precisely targeted approach that has been used in clinical studies for the diagnosis and treatment of cancer.
About NuView Life Sciences, Inc
NuView Life Sciences, Inc ("NuView") is a clinical stage company developing next-generation products to address the growing need for radiopharmaceuticals in oncology. NuView is a leader of in vitro and in vivo approaches to diagnose cancer with its proprietary NV-VPAC1™ platform. NuView's clinical stage in vitro liquid biopsy application is labeled with a fluorophore which fluoresces on the surface of shed cancer cells utilizing optical imaging. This application is also under development for use as a lateral flow strip pad test.
NuView's clinical stage in vivo theranostics platform designed to deliver "paired" Copper-64 (Cu-64) and Copper-67 (Cu-67) for precision diagnosis and targeted therapy will be used for a variety of cancers found to overexpress VPAC1 receptors on the cell surface. The VPAC1 receptor provides a highly efficacious target for precision diagnosis and targeted therapeutic delivery. To learn more, visit www.nuviewlifesciences.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Corporate Contact
Sherri Fitch
NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098
Office: +1.435.647.9758
E-mail: [email protected]
Investor/Media Contact
Jennifer K. Zimmons, PhD, MBA
President
Zimmons International Communications, Inc.
Phone: +1.917.214.3514
E-mail: [email protected]
SOURCE: NuView Life Sciences, Inc